In this interview, we discuss the results of the phase III MURANO trial, which tested the combination of venetoclax with rituximab in relapsed/refractory CLL.
In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.
In this interview we discuss the goals of therapy in multiple myeloma, treatment combinations and transplantation, and how markers such as minimal residual disease are used.
In this interview, we discuss the biology and the therapeutic strategies for primary mediastinal B-cell lymphoma.
In this interview ahead of the ASH Annual Meeting we discuss the current management of Philadelphia chromosome–positive acute lymphoblastic leukemia and the role of stem cell transplantation.
In this interview, we discuss an assay that can detect disease recurrence in colorectal cancer patients.
In this interview we discuss a recent study presented at ESMO on fertility-preserving procedures for women with BRCA-positive breast cancers
In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.
In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.